2023
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
Lu L, Ma W, Johnson C, Khan S, Irwin M, Pusztai L. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine 2023, 41: 2073-2083. PMID: 36813666, PMCID: PMC10064809, DOI: 10.1016/j.vaccine.2023.02.048.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmCA-125 AntigenCancer VaccinesEpitopes, T-LymphocyteFemaleHumansMRNA VaccinesOvarian NeoplasmsConceptsMRNA vaccinesOvarian cancerT cell responsesMutation-derived neoantigensT cell epitopesSARS-CoV-2Multiple neoantigensCytotoxic CD8Dendritic cellsCA 125Cancer vaccinesPatient survivalImmune responseCell epitopesNeoepitope peptidesNeoantigensVaccineCell responsesCancerBreastReverse vaccinologyCD8CD40LIFNNeoepitopes
2021
Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
Liu J, Huang X, Liu H, Wei C, Ru H, Qin H, Lai H, Meng Y, Wu G, Xie W, Mo X, Johnson CH, Zhang Y, Tang W. Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients. Journal Of Translational Medicine 2021, 19: 27. PMID: 33413474, PMCID: PMC7789428, DOI: 10.1186/s12967-020-02638-9.Peer-Reviewed Original ResearchConceptsKRAS mutant CRC patientsTumor-infiltrating immune cellsKRAS wild-type CRC patientsCD4 memory T cellsCRC patientsMemory T cellsColorectal cancerT cellsImmune pathwaysImmune cellsMacrophage M1Hypersensitive C-reactive proteinKRAS-mutant colorectal cancerCases of CRCKRAS mutantPrognostic immune-related genesImmune risk modelColorectal cancer patientsRegulatory T cellsC-reactive proteinTumor immune microenvironmentDistinct clinical outcomesT cell receptorImmune-related genesConclusionsKRAS mutation